my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
Cancer remains a medical mystery – despite all of the research efforts devoted to understanding and controlling it. The most sought-after tumor model is one that would be able to formulate theoretical and computational tools to predict cancer progression and propose individual treatment strategies. more
Santhera Pharmaceuticals announced an exclusive license agreement with BioLineRx, covering Santhera's pre-clinical melanocortin-4 receptor (MC-4R) antagonist program currently in development for the treatment of cancer cachexia. Under the agreement, BioLineRx acquires all rights to develop, sub-lice more
MorphoSys AG announced that it has been awarded a grant by the German Federal Ministry of Education and Research, BMBF. The funding of approximately EUR 1 million supports MorphoSys in accelerating the development of its HuCAL-based cancer program MOR202 into clinical development for the treatment o more
Cancer stem-like cells (CSLC) are crucial in tumor initiation and progression; however, the underlying mechanism for the self-renewal of cancer cells remains undefined. In the study, immunohistochemical analysis of specimens freshly excised from patients with lung adenocarcinoma showed that high exp more
Abstract Background Non‐viral lipid‐based gene delivery vectors have been shown to possess better stability and longer circulation time after surface PEG modification. However, surface PEGylation may decrease the transfection efficiency dramatically. Here, we address the hypothesis that down r more
Abstract The proviral insertion site in Moloney murine leukemia virus, or PIM proteins, are a family of serine/threonine kinases composed of three different isoforms (PIM1, PIM2, and PIM3) that are highly evolutionarily conserved. These proteins are regulated primarily by transcription and stabi more
Overview Business Strategy Management Team Board Of Directors Scientific Advisory Board Clinical Advisory Board From Heparin to Glycodrugs Endotis Pharma Drug Discovery Engine Targeted Diseases R&D Programs News 29/04/2010 Endotis reports the successful completion of Phase I clinical trials of the more
MEDIA ADVISORY Merrimack Pharmaceuticals’ MM-111 Phase 1/2 Trial Design to be Presented at the 2010 ASCO Annual Meeting MM-111 is one of the lead candidates in Merrimack’s pipeline of novel, cancer antibodies CAMBRIDGE, MA, June 3, 2010 – Merrimack Pharmaceuticals, Inc. announced t more
Printable version About us Our Products R & D Partnerships People Investor & Media TG4010 TG4023 TG4040 TG4001/RG3484 TG4023 (MVA-FCU1) IMMUNOTHERAPY AND TARGETED CHEMOTHERAPY FOR THE TREATMENT OF VARIOUS CANCERS Description TG4023 is being developed to treat primary tumors of the liver (HCC) and more
Watchlist
This is where you can add this topic to your personal favourites
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
